fosstodon.org: About · Status · Profiles directory · Privacy policy
Mastodon: About · Get the app · Keyboard shortcuts · View source code · v4.4.3
DATE: August 09, 2025 at 04:00PM
SOURCE: PSYPOST.ORG
** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------
TITLE: Antidepressant vortioxetine linked to greater cognitive and mood improvements in Alzheimer’s patients
A new study published in the Journal of Alzheimer’s Disease suggests that vortioxetine, an antidepressant with a unique multimodal mechanism, may offer greater benefits for both mood and cognitive function in people with Alzheimer’s disease who also experience depressive symptoms, compared to other commonly prescribed antidepressants. Over the course of a year, patients taking vortioxetine showed larger improvements in measures of memory, attention, and reasoning, as well as a greater reduction in depressive symptoms, than those taking escitalopram, paroxetine, or bupropion.
Alzheimer’s disease is a progressive neurodegenerative disorder that affects memory, thinking, and behavior. It is the most common cause of dementia in older adults, gradually impairing a person’s ability to carry out daily activities. Alongside cognitive decline, many people with Alzheimer’s also experience neuropsychiatric symptoms such as depression, anxiety, and apathy. Depression in Alzheimer’s is common and can intensify the difficulties posed by memory loss and disorientation, while also worsening quality of life for both patients and caregivers.
The high prevalence of depression in Alzheimer’s has led to increased prescribing of antidepressants in this population. Yet research on how these drugs affect cognitive function has been limited and sometimes conflicting. Certain antidepressants may worsen cognition due to side effects on neurotransmitter systems, while others could potentially support brain function.
Vortioxetine is of particular interest because, beyond its action on serotonin receptors, it also influences other neurotransmitter systems involved in learning and memory. Previous studies in people with depression and in those with mild cognitive impairment have hinted at cognitive benefits, but few have directly compared vortioxetine to multiple other antidepressants in patients with Alzheimer’s.
To address this gap, researchers Eduardo Cumbo and Daniela Migliore conducted a 12-month randomized, open-label study at the Neurodegenerative Disorders Unit in Caltanissetta, Italy. The analysis focused on 108 outpatients with mild Alzheimer’s disease and depressive symptoms. Participants were randomly assigned to receive either vortioxetine (n=36) or one of three other antidepressants—escitalopram, paroxetine, or bupropion (n=72 in total)—while continuing standard Alzheimer’s treatments such as cholinesterase inhibitors or memantine. Patients were assessed at the start of the study, after six months, and after twelve months.
Cognitive function was measured using several established tests. The Mini-Mental State Examination evaluated overall cognitive ability, including memory, orientation, and language. The Attentive Matrices test measured selective attention, while the Coloured Progressive Matrices assessed nonverbal reasoning and problem-solving. The Digit Span task tested verbal working memory. Depression severity was measured with the Hamilton Depression Scale and the Cornell Scale for Depression in Dementia.
By the end of the study, patients in all groups showed some improvement on cognitive tests, but gains were generally largest and most consistent in the vortioxetine group. On the Mini-Mental State Examination, vortioxetine-treated patients improved by nearly three points, a statistically significant change. They also showed significant gains in selective attention and nonverbal reasoning, while patients on other antidepressants tended to improve less, and in some cases, not significantly. Working memory scores improved slightly in the vortioxetine group but did not reach statistical significance.
When comparing groups directly, vortioxetine outperformed the other antidepressants on most cognitive measures. The difference was particularly notable when compared to paroxetine, which has anticholinergic properties that can impair cognition in older adults. Escitalopram and bupropion showed moderate improvements on some attention measures, but not to the same extent as vortioxetine.
The study also found that depressive symptoms decreased in all groups over the 12-month period, but the reduction was more pronounced in patients taking vortioxetine. On both depression scales, the vortioxetine group’s scores dropped by about seven points from baseline—an improvement considered clinically meaningful. Between-group comparisons showed that vortioxetine’s effect on depressive symptoms was statistically superior to that of the other antidepressants.
Side effects were relatively uncommon and generally mild. Nausea and headache were the most frequently reported with vortioxetine, occurring in about 8% of patients. Two participants—one on paroxetine and one on bupropion—discontinued treatment due to side effects. No serious adverse events or deaths occurred during the study.
The researchers note some limitations. The trial was conducted at a single site with a modest sample size, which may limit how well the findings apply to the wider Alzheimer’s population. It was also open-label, meaning patients and doctors knew which treatment was being given, which could introduce bias.
Importantly, only patients with mild Alzheimer’s were included, so the results may not extend to those with more advanced disease. The study also could not determine whether the observed cognitive improvements were due directly to vortioxetine’s pharmacological effects or indirectly through relief of depressive symptoms.
Despite these caveats, the findings add to a growing body of evidence suggesting that vortioxetine may have cognitive benefits beyond its antidepressant effects. The authors suggest that larger, longer-term, and double-blind studies are needed to confirm these results and to clarify how vortioxetine’s effects on neurotransmitter systems might influence both mood and cognition in people with Alzheimer’s.
If future research confirms these findings, vortioxetine could be considered a particularly useful option for Alzheimer’s patients who experience depression—addressing not only mood symptoms but also potentially helping to preserve certain cognitive functions.
The study, “Differential effects of antidepressants on cognition in Alzheimer’s disease with depression: A sub-group analysis of an open-label, observational study,” was authored by Eduardo Cumbo and Daniela Migliore.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot
Since 1991 The National Psychologist has focused on keeping practicing psychologists current with news, information and items of interest. Check them out for more free articles, resources, and subscription information: https://www.nationalpsychologist.com
EMAIL DAILY DIGEST OF RSS FEEDS -- SUBSCRIBE: http://subscribe-article-digests.clinicians-exchange.org
READ ONLINE: http://read-the-rss-mega-archive.clinicians-exchange.org
It's primitive... but it works... mostly...
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist
DATE: August 09, 2025 at 02:00PM
SOURCE: PSYPOST.ORG
** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------
TITLE: Neuroticism is linked to more frequent nightmares in adults
URL: https://www.psypost.org/neuroticism-is-linked-to-more-frequent-nightmares-in-adults/
People who score higher on neuroticism are more likely to experience frequent nightmares, according to research published in Dreaming.
Nightmares—vivid, emotionally intense dreams that often lead to waking—are quite rare, comprising about 3% of dreams on average. Yet for some individuals, they occur far more frequently and with significant emotional distress. Persistent nightmares can worsen mental health outcomes, increasing the risk of PTSD, suicidal ideation, and impaired daily functioning.
Past research has suggested that personality traits may play a role in who is more vulnerable to nightmares, but findings have been inconsistent, particularly regarding which of the Big Five personality traits (openness, conscientiousness, extraversion, agreeableness, and neuroticism) are most associated with nightmare frequency and distress.
Aurore Roland and Zosia Goossens conducted a systematic review and meta-analysis to clarify these associations.
To identify relevant studies, the authors conducted a systematic search across four major scientific databases, including PubMed, Embase, Scopus, and Web of Science, using a comprehensive set of search terms related to nightmares and the Big Five personality traits. To be included, studies had to examine adult participants, measure the Big Five traits using a validated questionnaire, and assess nightmare frequency or distress. Studies without full text, non-English publications, conference abstracts, and studies using alternative personality frameworks were excluded.
Ten studies met the inclusion criteria, all of which were rated as having a low risk of bias using the Joanna Briggs Institute Critical Appraisal Tool. Participant samples varied widely, including university students and general population adults, with sample sizes ranging from 117 to 2,492 individuals. Most studies used the NEO-FFI or BFI to measure personality traits and relied on either single-item or short-form scales to assess nightmare frequency and distress.
Due to differences in available data, the authors were able to conduct meta-analyses only for nightmare frequency in relation to openness (reflective of traits like imagination and creativity) and neuroticism (tendency to experience more frequent and intense negative emotions). Nightmare distress could not be meta-analyzed due to inconsistent reporting formats and insufficient correlational data.
The meta-analysis revealed a small but significant association between openness and nightmare frequency (Fischer’s z = .06). This suggests that while individuals high in openness may experience slightly more nightmares, the effect is minimal and likely not clinically meaningful. The result was consistent across different statistical models, including sensitivity analyses with and without regression-based data.
In contrast, the association between neuroticism and nightmare frequency was stronger (z = .30), indicating a small-to-moderate effect. People higher in neuroticism were significantly more likely to report frequent nightmares. Importantly, this result remained robust even when the authors excluded studies that reported only regression-based estimates, although the strength of the association did decrease slightly when such studies were included.
These findings underscore neuroticism as an important personality-based risk factor for frequent nightmares, highlighting the role of emotional instability in sleep-related distress.
One limitation is the small number of eligible studies, which limited the scope of meta-analyses and prevented analysis of other traits like agreeableness, conscientiousness, and extraversion.
The research, “Nightmares and the Big Five Personality Traits: A Systematic Review and Three-Level Meta-Analysis,” was authored by Aurore Roland and Zosia Goossens.
URL: https://www.psypost.org/neuroticism-is-linked-to-more-frequent-nightmares-in-adults/
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot
Since 1991 The National Psychologist has focused on keeping practicing psychologists current with news, information and items of interest. Check them out for more free articles, resources, and subscription information: https://www.nationalpsychologist.com
EMAIL DAILY DIGEST OF RSS FEEDS -- SUBSCRIBE: http://subscribe-article-digests.clinicians-exchange.org
READ ONLINE: http://read-the-rss-mega-archive.clinicians-exchange.org
It's primitive... but it works... mostly...
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist
Mastodon is the best way to keep up with what's happening.
Follow anyone across the fediverse and see it all in chronological order. No algorithms, ads, or clickbait in sight.
Login